期刊
CELLS
卷 10, 期 3, 页码 -出版社
MDPI
DOI: 10.3390/cells10030675
关键词
diffuse large B-cell lymphoma; gene expression profiling; next-generation sequencing; classification; diagnosis; prognosis; therapy
类别
资金
- Italian Association for Cancer Research (AIRC 5x1000 grant) [21198]
- Ministry of Health, Italian Government, Funds R.C. 2021
Diffuse large B-cell lymphoma is the most common form of lymphoid malignancy globally, with a classification including a common form and a series of rare variants. Recent studies have focused on identifying prognostic/predictive factors for the use of tailored therapies in patients.
Diffuse large B-cell lymphoma (DLBCL) is the commonest form of lymphoid malignancy, with a prevalence of about 40% worldwide. Its classification encompasses a common form, also termed as not otherwise specified (NOS), and a series of variants, which are rare and at least in part related to viral agents. Over the last two decades, DLBCL-NOS, which accounts for more than 80% of the neoplasms included in the DLBCL chapter, has been the object of an increasing number of molecular studies which have led to the identification of prognostic/predictive factors that are increasingly entering daily practice. In this review, the main achievements obtained by gene expression profiling (with respect to both neoplastic cells and the microenvironment) and next-generation sequencing will be discussed and compared. Only the amalgamation of molecular attributes will lead to the achievement of the long-term goal of using tailored therapies and possibly chemotherapy-free protocols capable of curing most (if not all) patients with minimal or no toxic effects.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据